Amid rapid scientific progress, familiar targets continue to capture momentum while promising alternatives struggle for visibility. A quiet cognitive bias shapes how opportunities are assessed and prioritized. For companies developing novel science, recognizing this pattern—and designing strategies that anticipate and counter it—will be essential to advancing differentiated programs in a landscape defined by precedent.

GLP-1 therapies transformed obesity & diabetes care and are now being explored for potential breakthroughs in neurological diseases.

AI promised faster drug discovery, lower costs, and reduced risk — but the reality has proven more nuanced. From an 80–90% Phase 1 success rate to high-profile pipeline cuts, this piece looks at where AI has genuinely delivered, where the hype has outpaced the science, and what it will take to build a credible, transparent path forward.

Organs-on-chips are at the forefront of preclinical innovation, promising to usher in a new era of patient-centric drug development.

Explore new targets for CRISPR-based therapeutics, as well as challenges associated with commercialization of these therapies.